BTLA inhibition has a dominant role in the cis-complex of BTLA and HVEM
Frontiers in Immunology, 2022 The engagement of the herpesvirus entry mediator (HVEM, TNFRSF14) by the B and T lymphocyte attenuator (BTLA) represents a unique interaction between an activating receptor of the TNFR-superfamily and an inhibitory receptor of the Ig-superfamily.
Judith Leitner +2 more
exaly +4 more sources
Babylon, 2016 Den danske regerings antiterrorstrategi strækker sig fra militære midler til dialog; et centralt begreb i regeringens såkaldte “Arabiske Initiativ” til fremme af partnerskaber om “fremskridt og reform” i Mellemøsten.
Ulrik Pram Gad
doaj +3 more sources
HVEM-LIGHT signaling promotes antibody-dependent neutrophil FcγR-mediated trogocytosis against herpes simplex virus infection [PDF]
The Journal of Clinical InvestigationStudies with a candidate vaccine deleted in glycoprotein D (ΔgD-2) for herpes simplex virus (HSV) prevention uncovered a role for herpes virus entry mediator (HVEM) in mediating antibody-dependent cell-mediated killing (ADCK) of virally infected cells ...
Matthew S. Gromisch +4 more
doaj +2 more sources
OncoImmunology, 2019 HVEM (Herpes Virus Entry Mediator) engagement of BTLA (B and T Lymphocyte Attenuator) triggers inhibitory signals in T cells and could play a role in evading antitumor immunity.
Caroline Gaudy-Marqueste +2 more
exaly +2 more sources
HVEM costimulatory domain boosts CAR T cell efficacy against solid tumors via enhanced TRAF-mediated TNF signaling [PDF]
Cell Communication and SignalingBackground Chimeric antigen receptor (CAR) T cell therapy has shown success in hematological malignancies, but its efficacy against solid tumors remains limited.
Shishuo Sun +14 more
doaj +2 more sources
Role of LIGHT in the Inflammatory Mechanisms of Psoriasis via Upregulation of Proliferation and Cytokine Production of Keratinocytes [PDF]
Immunity, Inflammation and DiseaseBackground The pathogenesis of psoriasis is associated with abnormalities in immune pathways. HVEM is known as a receptor of LIGHT (homologous to lymphotoxins, inducible, and competes with HSV glycoprotein D), which is a newly identified member of the ...
Cheng‐bin Ye +4 more
doaj +2 more sources
Partial or complete blocking of gD binding to HVEM affects primary and latent HSV-1 infection as well as eye disease in HSV-1 infected mice. [PDF]
PLoS PathogensHerpes simplex virus type 1 (HSV-1) glycoprotein D (gD) engages herpesvirus entry mediator (HVEM) and other cellular receptors to mediate efficient viral attachment.
Deepak Arya +4 more
doaj +2 more sources
BTLA-HVEM Couple in Health and Diseases: Insights for Immunotherapy in Lung Cancer
Frontiers in Oncology, 2021 Lung cancer is the leading cause of cancer deaths worldwide. Immunotherapies (IT) have been rapidly approved for lung cancer treatment after the spectacular results in melanoma.
Laurent Gorvel, Daniel Olive
exaly +3 more sources
Evaluation of LIGHT-derived peptides to disrupt the HVEM/LIGHT immune checkpoint [PDF]
Scientific ReportsImmune checkpoints are critical regulators of immune homeostasis and have become prominent targets in the treatment of various malignancies and autoimmune disorders. While monoclonal antibodies currently dominate checkpoint-targeted therapies, there is a
Piotr Ciura +5 more
doaj +2 more sources
FXR shapes an immunosuppressive microenvironment in PD-L1lo/– non-small cell lung cancer by upregulating HVEM [PDF]
JCI InsightImmune checkpoint therapy has changed cancer treatment, including non-small cell lung cancer (NSCLC). The unresponsiveness of PD-L1lo/– tumors to anti–PD-1/PD-L1 immunotherapy is attributed to alternative immune evasion mechanisms that remain elusive. We
Xiaolong Xu +11 more
doaj +2 more sources